Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 8.01 (Other Events). Constructive June 3 FDA Pre-IND meeting for ABO-701, PSMA-targeted engineered T-cell therapy for prostate cancer.
ABEONA THERAPEUTICS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Constructive June 3 FDA Pre-IND meeting for ABO-701, PSMA-targeted engineered T-cell therapy for prostate cancer
- IND submission remains targeted for 2027, supporting continued development of recently licensed program
- Official FDA minutes pending, creating potential for additional studies, data, or information requirements
- IND acceptance and clinical-trial authorization remain uncertain, with plans subject to FDA, preclinical, and manufacturing feedback
- Development may require additional equity funding or expense reductions, highlighting financing risk beyond regulatory execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ABEONA THERAPEUTICS INC. 8-K filings
Get the next ABEO 8-K as it lands
Follow ABEO for push alerts, or ask the research agent what this filing means.